UK adds nerve disorder as rare side-effect of AstraZeneca COVID-19 vaccine – Reuters

Oct 21 (Reuters) – The UK drug regulator added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), as a very rare side effect of the AstraZeneca (AZN.L) COVID-19 vaccine, updates on the agency’s website showed on Thursday.

Medicines and Healthcare products Regulatory Agency’s (MHRA) decision comes after the European medicines agency added GBS as a possible side-effect last month. read more

Reporting by Yadarisa Shabong in Bengaluru; Editing by Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.

Source